Empowering T cell therapies: the strategic use of LentiBOOST in CAR T and TCR modalities

A crucial step in the development of ACTs is the genetic modification of immune cells. A widely adopted method involves the use of lentiviral vectors, which are known for their efficiency in integrating therapeutic genes into target cell genomes.

Find out how the LentiBOOST™ transduction enhancer is being applied to CAR T and TCR modalities by scientists around the globe to help improve the effectiveness, scalability, cost, and safety of cell therapies in this literature review.

Why cell therapy leaders should read this resource:

• Insights into optimizing allogeneic CAR T therapy production
• Methods to enhance CAR T cell manufacturing to target ovarian cancer
• Strategies for improving CAR Treg transduction
• Approaches to overcome unique challenges in dual-targeting CAR T cell manufacturing
• Techniques for cord blood-derived T cell modification (TCR gene delivery)

LentiBOOST Pharma-Grade: For research use only.

Not for use in diagnostic procedures.LentiBOOST GMP Grade: Not for diagnostic use. Other applications must be authorized by a license from Revvity.